2.66
+0.035(+1.34%)
Currency In USD
| Previous Close | 2.62 |
| Open | 2.62 |
| Day High | 2.78 |
| Day Low | 2.61 |
| 52-Week High | 2.89 |
| 52-Week Low | 0.8 |
| Volume | 1.47M |
| Average Volume | 4.14M |
| Market Cap | 695.04M |
| PE | -8.05 |
| EPS | -0.33 |
| Moving Average 50 Days | 2.04 |
| Moving Average 200 Days | 1.78 |
| Change | 0.04 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $332.49 as of May 09, 2025 at a share price of $2.62. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $203.89 as of May 09, 2025 at a share price of $2.62.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
Akebia to Host Conference Call on May 8, 2025, at 8:00 a.m. EDTCAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31,
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
GlobeNewswire Inc.
Apr 03, 2025 12:00 PM GMT
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
GlobeNewswire Inc.
Mar 25, 2025 12:00 PM GMT
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the